Pfizer (PFE)

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet.

Apple and Cisco could generate surprising gains over the next few years.

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Bristol Myers Squibb just agreed to shower BioNTech with cash.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.

The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns.

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback.

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.

Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments.

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.